Update for January 18, 2022

Access 53 recently approved and available drugs and 22 investigational drugs on the short list for approval.

Last week we added 12 new drugs to the knowledgebase:

1. Spesolimab to treat generalized pustular psoriasis flares
2. Nemvaleukin to treat platinum-resistant ovarian cancer
3. Parsaclisib to treat relapsed or refractory non-hodgkin lymphomas
4. Isaralgagene civaparvovec to treat Fabry disease
5. Izokibep to treat ankylosing spondylitis
6. Icosabutate to treat nonalcoholic steatohepatitis (NASH)
7. Ensartinib to treat ALK-positive non-small cell lung cancer (NSCLC)
8. Simufilam to treat Mild to moderate Alzheimer's Disease
9. Ensovibep to treat COVID-19
10. Rencofilstat to treat nonalcoholic steatohepatitis (NASH)
11. C-CAR039 to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
12. BDC-1001 to treat HER2-expressing solid tumors

The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 970 pipeline and recently approved drugs by the following search parameters:

• 800 Indications
• 249 Approvals
• 663 manufacturers
• 26 Therapeutic classes
• Drugs with PDUFA Dates
• Recently approved drugs

Regulatory Update 

The FDA approved abrocitinib (Cibinqo, Pfizer), on 1/14/2022, for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic therapies. Like other JAK inhibitors, abrocitinib was approved with a boxed warning regarding the increased risk for serious infections, mortality, malignancy, major cardiovascular events and thrombosis.
 
Announced Research Updates 

Sarepta announced data from 20 patients enrolled in Part 2 of a 48-week, 41 patient, Phase II trial, where treatment with delandistrogene moxeparvovec improved the NSAA score by two points compared to a 103 patient, weighted external control group (1.3 point increase vs 0.7 point decrease).

We also added six new published research updates that subscribers can review

• Adding camrelizumab to carboplatin plus paclitaxel to treat advanced squamous non-small cell lung cancer.
• The combination of camrelizumab and apatinib in the treatment of advanced esophageal squamous cell carcinoma.
• Phase II results for the J&J ebola vaccine.
• Adding spartalizumab to dabrafenib and trametinib to treat BRAF V600-mutant unresectable or metastatic melanoma.
• Melflufen compared to pomalidomide to treat relapsed or refractory multiple myeloma patients who are receiving dexamethasone.
• Does adding radiotherapy to tremelimumab plus durvalumab improve the overall response rate in the treatment of metastatic non-small cell lung cancer resistant to PD-1 and PD-L1 targeted therapy?

Check out our new lower subscription rates and don't miss out on these clinical updates.